Key result
Review explores cilostazol use as global diabetes prevalence rises toward an expected ~10%.
Key points are not available for this paper at this time.
Population
Diabetic patients
Answers are grounded in this paper and cite their sources.
Cilostazol evaluation in diabetics should not yet change practice; leaves open its role as prevalence rises.
The International Diabetes Federation (IDF) reported that the global prevalence of diabetes (DM) in adults was 8.3% in 2013 expecting to rise beyond 592 million by 2035 with a 10.1% global prevalence [1]. Guidelines have been published for the treatment of this major disease and its complications [2,3].
No takes yet. Share an insight, caveat, or question.
Konstantine Spanos (2016) studied this question. Cilostazol use in diabetic patients is explored in the context of rising global diabetes prevalence from 8.3% in 2013 to an expected 10.1% by 2035.
Synapse has enriched 10 related papers. Consider them for comparative context: